Post Archive by Day

Vaccines Europe recently conducted a pipeline review of its member companies, revealing numerous vaccine innovations in development, including candidates that will protect international travelers.
In today's interconnected world, international travel increases the risk of spreading infectious diseases. According to an analysis, between 42% and 79% of travelers to low—and middle-income countries become ill with a travel-associated disease.

Since 1998, various respiratory syncytial virus (RSV) monoclonal antibody (mAb) therapies have been approved to prevent serious lower respiratory tract disease caused by RSV in young children.
Over the past two years, a single-dose, long-acting mAb designed to protect infants has been approved in Canada, Europe, and the USA.
As of March 2024, among females with an infant less than 8 months, 41.3% reported that their infant received an approved mAbs.